Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MedSmart Group Inc. (MSGP)
Bay Harbor Islands, FL, US
MedSmart Group Inc. oversees a network of professional MedSmart wellness centers, primarily dedicated to providing anti-aging solutions. Their comprehensive suite of services includes hormone replacement therapies, such as testosterone replacement and general hormone restoration, cryogen therapy, and treatments for various health issues like hypothyroidism, allergies, high cholesterol, hypertension, and diabetes. Furthermore, the centers offer specialized programs like the Smart Diet and Medi-Fast, alongside aesthetic and health-related procedures, including vein treatment, laser hair removal, hair loss solutions, and erectile dysfunction treatment. The company's headquarters are situated in Bay Harbor Islands, Florida.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | 0.00% | 0.00% | +20.00% | +500.00% | +20.00% | +500.00% | +50.00% | -99.95% | -99.88% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Care Facilities: +10.2%—
-
EPS growth Medical - Care Facilities: +19.2%+94.7% ★ Q3'22: -40.0% (vs Q3'21)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%—
-
EBIT margin Medical - Care Facilities: +11.3%—
-
ROIC Medical - Care Facilities: +6.8%— Q3'22: +106.4% (vs Q3'21)
-
Share dilution Medical - Care Facilities: +0.0%+2,466.8% Q3'22: +32.6% (vs Q3'21)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×— Q3'22: -9.36× (vs Q3'21)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kevin Earl Toto | 464.77M | 8.90% | — | 464.77M | — | 10.00 | IN | United States of America | 2013-07-11 | ↗ |
| 2 | Star City Capital, LLC | 10.00 | 12.00% | 19.07M | — | — | 19.07M | PN | New York | 2012-10-15 | ↗ |
| 3 | VERA Group, LLC | 10.00 | 12.00% | 22.00M | 22.00M | 22.00M | 22.00M | PN | South Dakota | 2012-11-20 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adel Nasser | Chief Executive Officer & Director | — | male |
| Davinder Dogra | President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MSGP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
